Cassava Sciences (MEX:SAVA) Debt-to-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Cassava Sciences Debt-to-Asset?

Cassava Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was MXN0.00 Mil. Cassava Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was MXN0.00 Mil. Cassava Sciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was MXN2,584.34 Mil. Cassava Sciences's debt to asset for the quarter that ended in Mar. 2024 was 0.00.

Cassava Sciences Debt-to-Asset Historical Data

The historical data trend for Cassava Sciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cassava Sciences Debt-to-Asset Chart

Cassava Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

Cassava Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cassava Sciences's Debt-to-Asset

For the Biotechnology subindustry, Cassava Sciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cassava Sciences's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cassava Sciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Cassava Sciences's Debt-to-Asset falls into.

Cassava Sciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Cassava Sciences's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	2574.365
	=	0.00

Cassava Sciences's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	2584.336
	=	0.00

Cassava Sciences (MEX:SAVA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Cassava Sciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Cassava Sciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Cassava Sciences (MEX:SAVA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cassava Sciences Inc (MEX:SAVA) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

SAVA:USA PX91:Germany

Address

6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731

Website

https://www.cassavasciences.com

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.